|
WO2015178770A1
|
|
Compositions for cancer treatment
|
|
WO2015156674A2
|
|
Method for treating cancer
|
|
WO2015041534A1
|
|
P90rsk in combination with raf/erk/mek
|
|
WO2015041533A1
|
|
Rock in combination with mapk-pathway
|
|
WO2014025258A1
|
|
A method for monitoring parp activity in cells by parp activation
|
|
EP2869835A1
|
|
Cysteine protease capturing agents
|
|
GB201308753D0
|
|
Compounds and their use in therapy
|
|
WO2013109142A1
|
|
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
GB201216730D0
|
|
Oligonucleotide-directed gene modification
|
|
EP2649091A1
|
|
Immune restricted peptides with increased efficacy
|
|
EP2619326A2
|
|
Methods for predicting response to anti-cancer therapy in cancer patients
|
|
EP2616479A1
|
|
Total chemical synthesis of ubiquitin, ubiquitin mutants and derivatives thereof
|
|
WO2012076059A1
|
|
Immune restricted peptides with increased efficacy
|
|
WO2011048499A1
|
|
Predicting response to anti-cancer therapy via array comparative genomic hybridization
|
|
WO2011048498A2
|
|
Differentiation between brca2-associated tumours and sporadic tumours via array comparative genomic hybridization
|
|
WO2011048495A1
|
|
Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
|
|
WO2011037462A1
|
|
Method for non-invasive quantitative assessment of radioactive tracer levels in the blood stream
|
|
EP2478101A1
|
|
Fra-1 target genes as drug targets for treating cancer
|
|
SG176085A1
|
|
Lysine compounds and their use in site- and chemoselective modification of peptides and proteins
|
|
EP2190413A2
|
|
Compositions for the treatment of neoplastic diseases
|
